TMO
Thermo Fisher Scientific Inc. [TMO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TMO Stock Summary
Top TMO Correlated Resources
TMO
Top 10 Correlated ETFs
TMO
Top 10 Correlated Stocks
TMO
In the News
New Strong Sell Stocks for December 6th
AESI, EQH and TMO have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2023.
Thermo Fisher (TMO) Advances Health Equity via New Partnership
Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.
Thermo Fisher Scientific: A Good Buy Near The Bottom
Thermo Fisher Scientific is facing temporary revenue headwinds due to reduced COVID-19-related sales and cautious customer spending. The company's organic revenues are expected to bottom in FY24 and see a reacceleration in growth from FY25 onwards which can help the stock re-rate. TMO's valuation is cheap compared to historical averages and peers, offering a good buying opportunity.
Thermo Fisher (TMO) Extends Partnership With Flagship Pioneering
Thermo Fisher's (TMO) in-depth knowledge of the life sciences sector will be combined with Flagship Pioneering to create revolutionary capabilities for the ecosystem.
3 High Dividend Growth Stocks to Buy in December 2023
After a downturn that ran from late summer to early fall, the stock market reversed higher on two pieces of good news. First, inflation seems to have stabilized.
Thermo Fisher Scientific reveals new $4B stock buyback program
Thermo Fisher Scientific (NYSE:TMO) Inc has announced a new $4 billion stock repurchase program, which represents about 2.3% of its market capitalization of $171.99 billion as of Monday's close. The analytics, diagnostics and laboratory services company said the new buyback program, which has no expiration date, replaces the existing program that had $1 billion in repurchase authorization remaining.
Thermo Fisher sets new $4 billion stock buyback program, about 2 weeks after shares hit a 3-year low
Shares of Thermo Fisher Scientific Inc. TMO, -0.73% were little changed in premarket trading Tuesday, after the analytics, diagnostics and laboratory services company announced a new $4 billion stock repurchase program. The new program represents about 2.3% of the company's market capitalization of $171.99 billion as of Monday's close.
Down 19% in 2023 So Far, Is Thermo Fisher Scientific Stock Still Worth Buying?
Thermo Fisher is seeing the collapse of its COVID-19 diagnostic business. It's also suffering from its customers tightening their purse strings.
Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
Thermo Fisher and Abbott are two of our key Healthcare holdings in our fund, and both are among our top 10 holdings overall. Abbott and Thermo Fisher focus on different industries which are Healthcare Equipment and Life Science Tools respectively. Both show strong revenue growth compared to the market average growth rate which indicates that both companies exhibit competitive advantages within their respective main markets.
3 Beaten-Down Dividend Stocks You Could Regret Not Buying on the Dip
Ally Financial is a digital bank that offers a dividend yield above 5% at recent prices. Thermo Fisher Scientific's COVID-19 testing revenue has evaporated, but that won't stop the company from raising its dividend payout higher in the years ahead.
TMO Financial details
TMO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 60.59 | 63.86 | 81.36 | 99.52 | 114.58 | |
| Net income per share | 7.31 | 9.24 | 16.1 | 19.61 | 17.73 | |
| Operating cash flow per share | 11.3 | 12.43 | 20.93 | 24.22 | 23.35 | |
| Free cash flow per share | 9.42 | 10.12 | 17.21 | 17.82 | 17.63 | |
| Cash per share | 5.23 | 6 | 26.07 | 11.36 | 21.74 | |
| Book value per share | 68.62 | 74.19 | 87.14 | 85.13 | 112.33 | |
| Tangible book value per share | -31.69 | -25.13 | -10.65 | -157.14 | -36.96 | |
| Share holders equity per share | 68.62 | 74.19 | 87.14 | 85.13 | 112.33 | |
| Interest debt per share | 48.9 | 46.07 | 56.28 | 89.86 | 89.83 | |
| Market cap | 89.96B | 129.95B | 184.45B | 262.89B | 215.87B | |
| Enterprise value | 106.85B | 145.3B | 195.86B | 293.29B | 241.83B | |
| P/E ratio | 30.62 | 35.16 | 28.93 | 34.03 | 31.06 | |
| Price to sales ratio | 3.69 | 5.09 | 5.73 | 6.7 | 4.81 | |
| POCF ratio | 19.8 | 26.13 | 22.25 | 27.55 | 23.58 | |
| PFCF ratio | 23.77 | 32.11 | 27.07 | 37.45 | 31.24 | |
| P/B Ratio | 3.26 | 4.38 | 5.35 | 7.84 | 4.9 | |
| PTB ratio | 3.26 | 4.38 | 5.35 | 7.84 | 4.9 | |
| EV to sales | 4.39 | 5.69 | 6.08 | 7.48 | 5.38 | |
| Enterprise value over EBITDA | 17.11 | 21.98 | 19.2 | 24.11 | 20.06 | |
| EV to operating cash flow | 23.52 | 29.22 | 23.63 | 30.73 | 26.42 | |
| EV to free cash flow | 28.23 | 35.9 | 28.74 | 41.78 | 34.99 | |
| Earnings yield | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Free cash flow yield | 0.04 | 0.03 | 0.04 | 0.03 | 0.03 | |
| Debt to equity | 0.69 | 0.6 | 0.63 | 1.04 | 0.78 | |
| Debt to assets | 0.34 | 0.31 | 0.31 | 0.37 | 0.35 | |
| Net debt to EBITDA | 2.7 | 2.32 | 1.12 | 2.5 | 2.15 | |
| Current ratio | 1.71 | 1.91 | 2.13 | 1.5 | 1.48 | |
| Interest coverage | 5.67 | 6.8 | 14.09 | 18.71 | 11.56 | |
| Income quality | 1.55 | 1.35 | 1.3 | 1.23 | 1.32 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.09 | 0.08 | 0.05 | 0.05 | 0.07 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | |
| Intangibles to total assets | 0.72 | 0.68 | 0.56 | 0.65 | 0.6 | |
| Capex to operating cash flow | -0.17 | -0.19 | -0.18 | -0.26 | -0.25 | |
| Capex to revenue | -0.03 | -0.04 | -0.05 | -0.06 | -0.05 | |
| Capex to depreciation | -0.33 | -0.41 | -0.63 | -0.97 | -0.66 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 106.23 | 124.19 | 177.66 | 193.79 | 211.68 | |
| ROIC | 0.05 | 0.06 | 0.09 | 0.09 | 0.07 | |
| Return on tangible assets | 0.19 | 0.2 | 0.21 | 0.24 | 0.18 | |
| Graham Net | -54.45 | -52.92 | -45.2 | -207.32 | -90.8 | |
| Working capital | 4.42B | 5.66B | 11.65B | 6.73B | 8.25B | |
| Tangible asset value | -12.74B | -10.05B | -4.22B | -61.92B | -14.49B | |
| Net current asset value | -17.96B | -16.65B | -12.59B | -74.6B | -27.78B | |
| Invested capital | 0.69 | 0.6 | 0.63 | 1.04 | 0.78 | |
| Average receivables | 4.01B | 4.24B | 5.05B | 6.86B | 8.13B | |
| Average payables | 1.52B | 1.77B | 2.05B | 2.52B | 3.12B | |
| Average inventory | 2.99B | 3.19B | 3.7B | 4.54B | 5.34B | |
| Days sales outstanding | 61.98 | 62.15 | 65.04 | 74.25 | 67.24 | |
| Days payables outstanding | 45.37 | 51.1 | 50.52 | 55.14 | 48.56 | |
| Days of inventory on hand | 84.41 | 89.69 | 93.59 | 97.15 | 80.91 | |
| Receivables turnover | 5.89 | 5.87 | 5.61 | 4.92 | 5.43 | |
| Payables turnover | 8.05 | 7.14 | 7.22 | 6.62 | 7.52 | |
| Inventory turnover | 4.32 | 4.07 | 3.9 | 3.76 | 4.51 | |
| ROE | 0.11 | 0.12 | 0.18 | 0.23 | 0.16 | |
| Capex per share | -1.89 | -2.32 | -3.72 | -6.4 | -5.72 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-10-01 | 2022-12-31 | 2023-04-01 | 2023-07-01 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 27.24 | 29.28 | 27.75 | 27.69 | 27.39 | |
| Net income per share | 3.81 | 4.03 | 3.34 | 3.53 | 4.44 | |
| Operating cash flow per share | 4.94 | 8.92 | 1.89 | 3.99 | 6.25 | |
| Free cash flow per share | 3.55 | 7.51 | 0.7 | 3.25 | 5.39 | |
| Cash per share | 7.45 | 21.8 | 9.02 | 8.12 | 15.94 | |
| Book value per share | 111.24 | 112.61 | 109.61 | 113.48 | 117.48 | |
| Tangible book value per share | -37.18 | -37.06 | -48.39 | -43.51 | -39.4 | |
| Share holders equity per share | 111.24 | 112.61 | 109.61 | 113.48 | 117.48 | |
| Interest debt per share | 74.83 | 88.89 | 92.12 | 88.95 | 92.34 | |
| Market cap | 198.82B | 215.32B | 222.48B | 201.4B | 195.38B | |
| Enterprise value | 225.06B | 241.28B | 254.25B | 232.27B | 224.51B | |
| P/E ratio | 33.25 | 34.16 | 43.15 | 36.99 | 28.48 | |
| Price to sales ratio | 18.62 | 18.81 | 20.77 | 18.84 | 18.48 | |
| POCF ratio | 102.64 | 61.75 | 305.18 | 130.78 | 80.94 | |
| PFCF ratio | 143.03 | 73.31 | 820.96 | 160.35 | 93.84 | |
| P/B Ratio | 4.56 | 4.89 | 5.26 | 4.6 | 4.31 | |
| PTB ratio | 4.56 | 4.89 | 5.26 | 4.6 | 4.31 | |
| EV to sales | 21.08 | 21.07 | 23.74 | 21.73 | 21.23 | |
| Enterprise value over EBITDA | 85.09 | 81.82 | 96.53 | 83.13 | 73.35 | |
| EV to operating cash flow | 116.19 | 69.2 | 348.77 | 150.83 | 93.01 | |
| EV to free cash flow | 161.91 | 82.15 | 938.21 | 184.93 | 107.84 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
| Debt to equity | 0.67 | 0.78 | 0.83 | 0.78 | 0.78 | |
| Debt to assets | 0.32 | 0.35 | 0.37 | 0.36 | 0.36 | |
| Net debt to EBITDA | 9.92 | 8.8 | 12.06 | 11.05 | 9.52 | |
| Current ratio | 1.74 | 1.48 | 1.27 | 1.42 | 1.63 | |
| Interest coverage | 9.88 | 6.92 | 5.21 | 4.84 | 5.19 | |
| Income quality | 1.29 | 2.22 | 0.56 | 1.13 | 1.42 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.08 | 0.07 | 0.09 | 0.1 | 0.08 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.64 | 0.6 | 0.65 | 0.65 | 0.63 | |
| Capex to operating cash flow | -0.28 | -0.16 | -0.63 | -0.18 | -0.14 | |
| Capex to revenue | -0.05 | -0.05 | -0.04 | -0.03 | -0.03 | |
| Capex to depreciation | -0.65 | -0.65 | -0.53 | -0.33 | -0.39 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | -0.01 | -0.01 | |
| Graham number | 97.7 | 101.06 | 90.75 | 94.88 | 108.37 | |
| ROIC | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Return on tangible assets | 0.05 | 0.04 | 0.04 | 0.04 | 0.05 | |
| Graham Net | -89.99 | -91.04 | -103.55 | -99 | -94.46 | |
| Working capital | 8.18B | 8.25B | 4.33B | 5.88B | 8.93B | |
| Tangible asset value | -14.57B | -14.49B | -18.68B | -16.8B | -15.21B | |
| Net current asset value | -27.51B | -27.78B | -32.02B | -30.2B | -28.5B | |
| Invested capital | 0.67 | 0.78 | 0.83 | 0.78 | 0.78 | |
| Average receivables | 7.71B | 7.97B | 8.1B | 7.97B | 8.19B | |
| Average payables | 2.53B | 2.93B | 3.09B | 2.61B | 2.47B | |
| Average inventory | 5.7B | 5.68B | 5.65B | 5.66B | 5.53B | |
| Days sales outstanding | 64.66 | 65.04 | 66.57 | 67.53 | 71.24 | |
| Days payables outstanding | 35.61 | 45.31 | 39.12 | 34.49 | 36.73 | |
| Days of inventory on hand | 82.45 | 75.51 | 79.19 | 80.49 | 79.15 | |
| Receivables turnover | 1.39 | 1.38 | 1.35 | 1.33 | 1.26 | |
| Payables turnover | 2.53 | 1.99 | 2.3 | 2.61 | 2.45 | |
| Inventory turnover | 1.09 | 1.19 | 1.14 | 1.12 | 1.14 | |
| ROE | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | |
| Capex per share | -1.4 | -1.41 | -1.19 | -0.74 | -0.86 |
TMO Frequently Asked Questions
What is Thermo Fisher Scientific Inc. stock symbol ?
Thermo Fisher Scientific Inc. is a US stock , located in Waltham of Ma and trading under the symbol TMO
Is Thermo Fisher Scientific Inc. buy or a sell ?
26 stock analysts have 26 predictions with a medium analyst target price of $635.38. The lowest prediction is $505 and the highest is $711
What is TMO stock prediction ?
With a median analyst target price of $530, 1 stock analysts have made 1 forecasts in last 90 days. $530 is the lowest and $530 is the greatest projection.
What is Thermo Fisher Scientific Inc. stock quote today ?
Thermo Fisher Scientific Inc. stock price is $489.77 today.
Is Thermo Fisher Scientific Inc. stock public?
Yes, Thermo Fisher Scientific Inc. is a publicly traded company.
Company Profile
- Volume Average 1.83M
- Market Capitalization 189.23B
- Employee 130K
- CEO Mr. Marc N. Casper
- Headquarters Waltham,MA,US
- IPO Date 1980-03-17
-
Website
https://www.thermofisher.com 
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
